Cyclo Therapeutics Stock Net Asset
| CYTHDelisted Stock | USD 0.72 0.06 9.09% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Cyclo Therapeutics' long-term financial health and intrinsic value.
Cyclo |
Cyclo Therapeutics Company Net Asset Analysis
Cyclo Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Cyclo Therapeutics Net Asset | 13.25 M |
Most of Cyclo Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Cyclo Therapeutics has a Net Asset of 13.25 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Cyclo Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in net asset category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | |||
| Return On Asset | -2.84 | |||
| Operating Margin | (35.46) % | |||
| Current Valuation | 34.87 M | |||
| Shares Outstanding | 32.74 M | |||
| Shares Owned By Insiders | 48.45 % | |||
| Shares Owned By Institutions | 11.44 % | |||
| Number Of Shares Shorted | 736.31 K | |||
| Price To Book | 59.10 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 1.08 M | |||
| Gross Profit | 794.48 K | |||
| EBITDA | (20.03 M) | |||
| Net Income | (20.06 M) | |||
| Cash And Equivalents | 4.29 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.03 M | |||
| Current Ratio | 2.93 X | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | (16.19 M) | |||
| Short Ratio | 5.58 X | |||
| Earnings Per Share | (0.90) X | |||
| Target Price | 0.95 | |||
| Beta | -0.57 | |||
| Market Capitalization | 23.59 M | |||
| Total Asset | 13.25 M | |||
| Retained Earnings | (83.86 M) | |||
| Working Capital | 3.85 M | |||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Cyclo Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |